Zelira Therapeutics Ltd. · ASX:ZLD
Zelira Therapeutics — Investor Presentation (July 2020)
16 slides from Zelira Therapeutics's investor presentation, Jul 9, 2020
Slide 1: Zelira Therapeutics
For personal use only ZELIRA THERAPEUTICS A GLOBAL BIOPHARMACEUTICAL COMPANY DEVELOPING AND MARKETING CLINICALLY VALIDATED CANNABIS MEDICINES ASX: ZLD OTCQB: ZLDAF WWW.ZELIRATX.COM
Slide 2: Disclaimer & Important Notice
DISCLAIMER & IMPORTANT NOTICE Disclaimer For personal use only This presentation has been prepared by Zelira Therapeutics Ltd ACN 103 782 378 (“Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Com
Slide 3: Company Overview
COMPANY OVERVIEW A global biopharmaceutical company developing, and marketing clinically validated cannabis medicines. For personal use only Global markets strategy Clinical validation focus Global product launch US, Australia and EU footprint to rapidly US, Australia and EU footprint to rapidly Lea
Slide 4: Investor Highlights
INVESTOR HIGHLIGHTS For personal use only Global access to the world’s largest and fastest growing cannabis markets Early mover advantage addressing need for clinically validated cannabis medicines Leading portfolio of validated products launching in 2020 Marketing strategy focused on differentiated
Slide 5: Launch, Learn & Develop for Rapid Commercialisation
For personal use only “LAUNCH, LEARN & DEVELOP” FOR RAPID COMMERCIALISATION LAUNCH LEARN DEVELOP • Generate proprietary formulations • Collect real-world patient data • Patient data informs and de-risks design of clinical trial • Launch products in global markets • Refine product to meet patient nee
Slide 6: Zelira's Global Commercialisation Strategy
ZELIRA’S GLOBAL COMMERCIALISATION STRATEGY VALUE ADDING For personal use only • Clinically validated/Real World Design key Data pre-clinical • Proprietary formulations and clinical studies • GMP-grade Branding Attracts Revenues from Global • IP protection • Branded Price Premium Distribution/Licensi
Slide 7: Global Market Opportunities
GLOBAL MARKET OPPORTUNITIES AUSTRALIA GERMANY USA For personal use only 25M 2019 population 83M 2019 population 330M 2019 population 11K 65K 4M Registered medical Registered medical Registered medical cannabis patients1 cannabis patients2 cannabis patients4 30-50K 90% Pennsylvania Louisiana Forecast
Slide 8: Multiple Product Launches Planned for 2020
For personal use only MULTIPLE PRODUCT LAUNCHES PLANNED FOR 2020 8
Slide 9: HOPE for Autism
For personal use only HOPE FOR ™ AUTISM H OAutism P E ™ FTherapeutic O R A U T I SMarket M • HOPE™ developed with and for the Autistic community • Survey suggests HOPE™ improves autism-related behaviors Revenues: Licensed in Pennsylvania & Louisiana (Deal Structure: Upfronts + double digit royalty)
Slide 10: Zenivol: World's First Clinically Validated Cannabis Drug for Chronic Insomnia
ZENIVOL™: WORLD’S FIRST CLINICALLY VALIDATED CANNABIS DRUG FOR CHRONIC INSOMNIA For personal use only ZENIVOL™: PATH TO MARKET • Phase 1B/2A clinical trial confirmed Zenivol™ safe, efficacious and improved quality of life • 36% Reduction in Insomnia Symptoms Manufacturing agreement for Australia: Ta
Slide 11: Rich Product Pipeline Launching in 2020
RICH PRODUCT PIPELINE LAUNCHING IN 2020 On-track to launch 5 products in 2020 For personal use only Launch Market 1H 2020 2H 2020 HOPE™ for Autism Launched 2H 2020 Insomnia (Zenivol™) (2020) Revenues Aged Disorder (2020) 2H 2020 Dermatology (2021) Targeted Pain/GI (2021) 11
Slide 12: Zelira's Five Sources of Revenues
ZELIRA’S FIVE SOURCES OF REVENUES For personal use only LAUNCH & CLINICAL ORAL LEARN TRIALS HEALTH DERMATOLOGY PHARMA Autism Insomnia Toothpaste RX Pain Aged disorders Opioid Sparing Mouth Wash Full Spec CBD GI Autism Consumer Brand OTC 13
Slide 13: Corporate Snapshot
CORPORATE SNAPSHOT FINANCIALS (as at 8th July 2020) For personal use only AUD$ Share Price $0.058 SHARE PRICE (as at 8 July 2020) 52w Range $0.022 - 0.091 Current shares on issue 966m Market Capitalisation 56m Cash (March 2020) $4.02m Cash Burn (2019FY) $2.6m CAPITAL STRUCTURE (Fully Diluted2) Struc
Slide 14: Global Board of Directors
GLOBAL BOARD OF DIRECTORS UNITED STATES AUSTRALIA For personal use only Osagie Imasogie: Chairman Harry Karelis: Vice Chairman • Over 30 years in the field of law, finance, business management, • Founding Director/Shareholder of numerous ASX-listed companies healthcare and the pharmaceutical industr
Slide 15: Upcoming Milestones
UPCOMING MILESTONES For personal use only Phase 2 Insomnia Trial - Successfully achieved primary and secondary endpoints. Phase 1 Dose Escalation Chronic Pain Trial Fully recruited. Manufacturing agreement for Insomnia HOPE™ Products Licensing deal for third party to fund new pain trial in retired a
Slide 16: For personal use only
For personal use only ZELIRA THERAPEUTICS OFFERS INVESTORS EXPOSURE TO A RAPIDLY EMERGING GLOBAL INDUSTRY AT VERY ATTRACTIVE VALUATIONS AND SIGNIFICANT VALUE DRIVERS OVER THE NEXT 3-18 MONTHS 17
Zelira Therapeutics — Investor Presentation (July 2020) on 6ix